Biopharmaceutical Analysis eBook
Read the article:
Complex Biomolecules Require Analytical Evolution
Read the ebook:
BioPharm International’s Biopharmaceutical Analysis eBook
The ever-increasing complexity of biotherapeutic molecules presents unique analytical challenges for developers.
Kateryna_Kon/Stock.adobe.com
The structure and activity of complex biotherapeutic molecules require sensitive analytical technologies that can characterize these complicated protein structures and observe their pharmacokinetic activity, elements fundamental to biotherapeutic drug development and production. Relevant technologies are needed to make detailed analytical assessments of structure, function, and purity, and further innovation is needed to address the continued challenge faced by the industry, including approaches to analytical method development and multiple analytical assays.
Read the article:
Complex Biomolecules Require Analytical Evolution
Read the ebook:
BioPharm International’s Biopharmaceutical Analysis eBook
Read this article in BioPharm International’s July 2021 Biopharmaceutical Analysis eBook.
Feliza Mirasol is the science editor for BioPharm International.
BioPharm International
eBook: Biopharmaceutical Analysis, July 2021
July 2021
Pages: 4–8
When referring to this article, please cite it as F. Mirasol, “Complex Biomolecules Require Analytical Evolution," BioPharm International Biopharmaceutical Analysis eBook (July 2021).
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.